Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-03-05
2008-09-09
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S308000, C435S377000
Reexamination Certificate
active
07423019
ABSTRACT:
A partial peptide of a preproglucagon peptide comprising at least the amino acid sequence at positions92-97of a preproglucagon peptide is used as an effective ingredient of an antidiabetic drug.
REFERENCES:
patent: 6284727 (2001-09-01), Kim et al.
patent: 2004/0037826 (2004-02-01), Michelsen et al.
patent: WO 98/08871 (1998-05-01), None
Shimon, American Journal of Pharmacogenomics : genomics-related research in drug development and clinical practice, (2002) vol. 2, No. 2, pp. 129-134, Abstract PubMed ID: 12083947.
Anonymous, Harvard health letter / from Harvard Medical School, (May 2002) vol. 27, No. 7, p. 6.
Bataille, D. et al. “Glucagon and Related Peptides”,Annals New York Academy of Sciences, vol. 527 pp. 168-185, 1988.
Bataille, D. et al. “Bioactive Enteroglucagon (Oxyntomodulin): Present Knowledge on Its Chemical Structure and Its Biological Activities”, Peptides, vol. 2 pp. 41-44, 1981.
Mojsov, S. et al. “Insulinotropin: Glucagon-like Peptide I (7-37) Co-encoded in the Glucagon Gene Is a Potent Stimulator of Insulin Release in the Perfused Rat Pancreas”,J. Clin. Invest., vol. 79 pp. 616-619, 1987.
Abraham, E.J. et al. “Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells”,Endocrinology, vol. 143(8) pp. 3152-3161, 2002.
Gutniak, M. et al. “Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus”,The New England Journal of Medicine, vol. 326(20) pp. 1316-1322, 1992.
Ghiglione, M. et al. “How glucagon-like is glucagons-like peptide-1?”,Diabetologia, vol. 27 pp. 599-600, 1984.
Schmidt, W.E. et al. “Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets”,Diabetologia, vol. 28 pp. 704-707, 1985.
Drucker, D.J. “Glucagon and the Glucagon-like Peptides”,Pancreas, vol. 5(4) pp. 484-488, 1990.
Kojima, H., et al., “Combined Expression Of Pancreatic Duodenal Homeobox 1 And Islet Factor 1 Induces Immature Enterocytes To Produce Insulin”,Diabetes, vol. 51, No. 5, pp. 1398-1408, (2002).
Drucker, D.J., “Glucagon-Like Peptides: Regulators Of Cell Proliferation, Differentiation, And Apoptosis”,Molecular Endocrinology, vol. 17, No. 2, pp. 161-171, (2003).
Suzuki, A., et al., “Glucagon-Like Peptide 1 (1-37) Converts Intestinal Epithelial Cells Into Insulin-Producing Cells”,Proc. Natl. Acad. Sci. USA, vol. 100, No. 9, pp. 5034-5039, (2003).
Eto Yuzuru
Suzuki Atsushi
Taniguchi Hideki
Ajinomoto Co. Inc.
Gamett Daniel C
Hopkins Susanne M.
Nath Law Group
Romeo David
LandOfFree
Agent for inducing conversion of intestinal cells into... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for inducing conversion of intestinal cells into..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for inducing conversion of intestinal cells into... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989516